Shanghai CAS Shenglongda Biotech (Group) Co. Ltd.

This study used alendronate sodium as a positive control drug to evaluate the efficacy and safety of recombinant human parathyroid hormone (1-34) for injection in the treatment of osteoporosis in postmenopausal women, and to provide support for the registration and marketing of the trial drug.

Using salmon calcitonin nasal spray and teriparatide injection as positive controls, the dose-effect relationship and safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in postmenopausal women were explored and evaluated, providing a basis for determining the safe and effective dose of the test drug in Phase III clinical trials.